Andrea Snow‐Lampart, Brandi Chappell, Maria Curtis, Yuao Zhu, Florence Myrick, James Schawalder, Kathryn Kitrinos, Evguenia S. Svarovskaia, Michael D. Miller, Jeff Sorbel, Jenny Heathcote, Patrick Marcellin, Katyna Borroto‐Esoda – 18 November 2010 – Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue with potent activity against human immunodeficiency virus type 1 and hepatitis B virus (HBV). To date, no reports of HBV clinical resistance to TDF have been confirmed.

Yingjun Zhao, Xiaoying Wang, Tao Wang, Xin Hu, Xin Hui, Mingxia Yan, Qiang Gao, Taoyang Chen, Jinjun Li, Ming Yao, Dafang Wan, Jianren Gu, Jia Fan, Xianghuo He – 18 November 2010 – Acetylcholinesterase (ACHE) plays important roles in the cholinergic system, and its dysregulation is involved in a variety of human diseases. However, the roles and implications of ACHE in hepatocellular carcinoma (HCC) remain elusive.

Hance Clarke, Tony Chandy, Coimbatore Srinivas, Salima Ladak, Nobuhiko Okubo, Nicholas Mitsakakis, Susan Holtzman, David Grant, Stuart A. McCluskey, Joel Katz – 16 November 2010 – Despite the increase in surgical volumes of live liver donation, there has been very little documentation of the postoperative pain experience.

Sanjaya K. Satapathy, Michael R. Charlton – 16 November 2010

Christopher D. Anderson, Gundumi Upadhya, Kendra D. Conzen, Jianlou Jia, Elizabeth M. Brunt, Venkataswarup Tiriveedhi, Yan Xie, Sabarinathan Ramachandran, Thalachallour Mohanakumar, Nicholas O. Davidson, William C. Chapman – 16 November 2010 – Hepatic steatosis continues to present a major challenge in liver transplantation. These organs have been shown to have increased susceptibility to cold ischemia/reperfusion (CIR) injury in comparison with otherwise comparable lean livers; the mechanisms governing this increased susceptibility to CIR injury are not fully understood.

Robert M. Merion – 16 November 2010

Franco Bonaguidi – 16 November 2010

Hongqun Liu, Samuel S. Lee – 16 November 2010

Giovanni Musso, Roberto Gambino, Maurizio Cassader – 12 November 2010

Yu‐Xiong Feng, Tao Wang, Yue‐Zhen Deng, Pengyuan Yang, Jing‐Jing Li, Dong‐Xian Guan, Fan Yao, Yin‐Qiu Zhu, Ying Qin, Hui Wang, Nan Li, Meng‐Chao Wu, Hong‐Yang Wang, Xiao‐Fan Wang, Shu‐Qun Cheng, Dong Xie – 12 November 2010 – Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is as high as 70%, and this gravely jeopardizes the therapeutic outcome. Clearly, new approaches are needed for preventing the relapse of this deadly disease.